Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* HbA1c ≥ 7%~* Age ≥ 18~Exclusion Criteria:~* Contraindication to Vildagliptin~* Pregnant or breast feeding women~* Type 1 diabetes, gestational diabetes, or diabetes with secondary cause~* Chronic hepatitis B or C (except healthy carrier of HBV)~* Liver disease (AST/ALT \> 3-fold the upper limit of normal)~* Renal failure (Cr \> 2.0)~* Cancer within 5 years~* Not appropriate for oral antidiabetic agent~* Medication which affect glycemic control~* Disease which affect efficacy and safety of drugs~* Other clinical trial within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (Type: EXPERIMENTAL): Vildagliptin will be added to uncontrolled diabetic patients with sulphonylurea and metformin
- Sulphonylurea dose-up (Type: ACTIVE_COMPARATOR): Sulphonylurea dose will be increased to uncontrolled diabetic patients with sulphonylurea and metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).